



October 29, 2019

Whom It May Concern

Company: KYORIN Holdings, Inc.
Representative: Yutaka Ogihara
Representative Director, President
(Security Code: 4569, TSE 1st Sec.)
Contact: Yoshinori Tanifuji
Director, Management Strategy &
Planning Division Corporate Planning
Telephone: 03-3525-4707

Release of Microchannel-based Genetic Measurement Device GeneSoC®

KYORIN Pharmaceutical Co., Ltd. (head office: Chiyoda-ku, Tokyo; President and CEO: Shigeru Ogihara; “KYORIN Pharmaceutical”), which is a subsidiary of KYORIN Holdings, Inc., will release a microchannel-based genetic measurement device GeneSoC® (“GeneSoC®”) and a special-purpose measurement chip based on a basic sales agreement concluded with AS ONE Corporation (head office: Nishi-ku, Osaka; President and CEO: Takuji Iuchi; “AS ONE”).

Under the Agreement, KYORIN Pharmaceutical will conduct promotional activities jointly with AS ONE, and AS ONE will sell GeneSoC® as laboratory equipment through its nationwide distribution network.

These products are scheduled to be released on November 11, and a measuring reagent specifically designed for GeneSoC® will also be launched subsequently.

GeneSoC® is a compact, super-fast genetic measuring device. It applies microchannel-based thermal cycle technology¹ developed by the National Institute of Advanced Industrial Science and Technology (“AIST”) and was developed jointly by KYORIN Pharmaceutical and AIST. GeneSoC® can identify a target gene in a sample in a short space of time (around 5-15 minutes). As a compact, super-fast genetic measuring device that can identify genes of humans, animals, plants, microorganisms and drug resistance genes in microorganisms quickly, accurately and simply, this device is expected to be applied in basic and clinical research and in testing for and diagnosing infections and other conditions.

Through the diagnostics using GeneSoC®, KYORIN Pharmaceutical aims to further contribute to infection control by establishing a business model for the prevention, diagnosis and treatment of infectious diseases and constantly providing relevant up-to-date information.

GeneSoC® Product Outline

- Rapid gene detection (around 5-15 minutes) based on super-fast quantitative PCR technology*2
- Desktop PCR device which has been made more compact in anticipation of POCT*3



*1 Microchannel-based thermal cycle technology: Technique for performing PCR by repeatedly moving the measurement sample backward and forward in a microchannel (specially designed measurement chip) heated by contact with multiple heaters. KYORIN Pharmaceutical has been granted an exclusive license to use this technology by AIST

*2 PCR (Polymerase Chain Reaction): Polymerase Chain Reaction or PCR is a technique used amplify a gene.

*3 POCT (Point of Care Testing): Testing carried out by healthcare professionals at the patient's bedside

The impact of the release of this product on KYORIN Holdings' consolidated operating results for the fiscal year ending March 31, 2020 is minor.

For Reference

◆ About AS ONE Corporation

Established in: 1962

President: Takuji Iuchi

Revenue: JPY66,733.18 million (fiscal year ended March 21, 2019)

Number of employees: 557 (as of March 31, 2019)

Description of business: Sale of research instruments / equipment, nursing / care products, other scientific instruments

Overview: Established as Iuchi Seieido Store in 1933, the business changed its company name to AS ONE Corporation upon listing on the first section of the Tokyo Stock Exchange in 2001. AS ONE Corporation is a general trading firm for scientific equipment. It has a unique business model, selling almost 4 million items for research, industry and medical fields via distributors through the use of catalogues and the Internet. AS ONE Corporation contributes to the development of science and technology by playing a crucial role in the distribution of a wide range of specialist products, services and information sought after by researchers and by providing added value.